Singapore ADC Specialist Axcynsis Nets Novel Payload To Address Drug Resistance

Axcynsis is developing a derivative of the chemotherapy agent Yondelis as a new payload, which the Singapore venture will first apply to a Claudin 6-targeting ADC it plans to take into a Phase I trial in the US, its chairman, CEO and founder tells Scrip in an interview.

target cancer — Axcynsis finds novel ADC payload in chemotherapy drug trabectedin • Source: Shutterstock

In a shot at repeating Daiichi Sankyo Co., Ltd.’s hugely successful development of deruxtecan as a cytotoxic payload, the holy grail in the design of antibody-drug conjugates (ADCs), Singapore-based Axcynsis Therapeutics is searching for a novel payload within approved chemotherapy drugs.

Its first such try is focusing on a derivative of Johnson & Johnson/

Key Takeaways

Singapore-based Axcynsis Therapeutics aims to develop the chemotherapy drug Yondelis (trabectedin) as a payload for antibody-drug conjugates.
Axcynsis sees opportunities in rising drug resistance to other payloads such as topoisomerase I inhibitors and tubulin inhibitors including auristatins, according to CEO Bin Zou

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

19 May 2025

• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

19 May 2025

• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

19 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.